RT Book, Section A1 Smith, Judith A. A2 Chisholm-Burns, Marie A. A2 Schwinghammer, Terry L. A2 Malone, Patrick M. A2 Kolesar, Jill M. A2 Lee, Kelly C. A2 Bookstaver, P. Brandon SR Print(0) ID 1174273301 T1 Ovarian Cancer T2 Pharmacotherapy Principles and Practice, 5e YR 2018 FD 2018 PB McGraw-Hill Education PP New York, NY SN 9781260019445 LK ppp.mhmedical.com/content.aspx?aid=1174273301 RD 2024/03/28 AB Content UpdateMay 28, 2020Selpercatinib Approved for Treatment of RET Fusion-Positive Non-small-cell Lung Cancer (NSCLC) And Thyroid Cancer:Selpercatinib (Retevmo) is indicated for adults with RET fusion-positive NSCLC and adults and children older than age 12 with RET fusion-positive thyroid cancer. A trial involving 144 patients with NSCLC and 143 patients with thyroid cancer who had advanced or metastatic RET fusion-positive disease gave patients selpercatinib 160 mg orally twice a day. The overall response rate was 64% (95% CI: 54%, 73%) in NSCLC patients who received prior therapy, 69% (95% CI: 55%, 81%) in treatment-naïve individuals, and 73% (95% CI: 62%, 82%) in treatment-naïve patients with thyroid cancer. Common adverse effects were diarrhea and hypertension.